Abcellera Biologics Inc (ABCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has a cash flow conversion efficiency ratio of -0.030x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.74 Million) by net assets ($1.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abcellera Biologics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Abcellera Biologics Inc total liabilities for a breakdown of total debt and financial obligations.
Abcellera Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abcellera Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHOP APOTH. UNSP.ADR/010
F:SAE1
|
N/A |
|
Fiskars Oyj Abp
HE:FSKRS
|
0.020x |
|
Shenzhen Bromake New Material Co. Ltd. A
SHE:301387
|
N/A |
|
Shenzhen Chuangyitong Technology Co.Ltd.
SHE:300991
|
-0.017x |
|
Brighton-Best International Taiwan
TWO:8415
|
0.015x |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
-0.003x |
|
MAGYAR TELE.A ADR/5 UF100
F:MGYA
|
N/A |
|
Jintuo Technology Co Ltd
SHG:603211
|
N/A |
Annual Cash Flow Conversion Efficiency for Abcellera Biologics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Abcellera Biologics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.14 Billion | $-131.29 Million | -0.115x | -11.91% |
| 2024-12-31 | $1.06 Billion | $-108.56 Million | -0.103x | -169.95% |
| 2023-12-31 | $1.15 Billion | $-43.88 Million | -0.038x | -116.93% |
| 2022-12-31 | $1.23 Billion | $277.36 Million | 0.225x | -5.68% |
| 2021-12-31 | $1.03 Billion | $244.58 Million | 0.238x | +772.78% |
| 2020-12-31 | $830.51 Million | $22.69 Million | 0.027x | -89.60% |
| 2019-12-31 | $10.25 Million | $2.69 Million | 0.263x | -14.43% |
| 2018-12-31 | $11.61 Million | $3.56 Million | 0.307x | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more